{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T19:23:06Z","timestamp":1774898586614,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,1,9]],"date-time":"2006-01-09T00:00:00Z","timestamp":1136764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,1,9]],"date-time":"2006-01-09T00:00:00Z","timestamp":1136764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2006,2,1]]},"DOI":"10.1038\/sj.bmt.1705245","type":"journal-article","created":{"date-parts":[[2006,1,9]],"date-time":"2006-01-09T08:48:40Z","timestamp":1136796520000},"page":"353-358","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis"],"prefix":"10.1038","volume":"37","author":[{"given":"R","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Chakrabarti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Akin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Robyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Bahceci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Greene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Childs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C E","family":"Dunbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D D","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A J","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,1,9]]},"reference":[{"key":"BF1705245_CR1","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","volume":"55","author":"C Akin","year":"2004","unstructured":"Akin C, Metcalfe DD . Systemic mastocytosis. Annu Rev Med 2004; 55: 419\u2013432.","journal-title":"Annu Rev Med"},{"key":"BF1705245_CR2","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S0145-2126(01)00046-7","volume":"25","author":"DD Metcalfe","year":"2001","unstructured":"Metcalfe DD, Akin C . Mastocytosis: molecular mechanisms and clinical disease heterogeneity. Leuk Res 2001; 25: 577\u2013582.","journal-title":"Leuk Res"},{"key":"BF1705245_CR3","first-page":"49","volume-title":"Tumours of Hematopoietic and Lymphoid Tissues","author":"E Jaffe","year":"2001","unstructured":"Jaffe E, Harris LH, Stein H, Vardiman J . Tumours of Hematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001, pp. 49\u201355. Ref Type: Generic."},{"key":"BF1705245_CR4","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1046\/j.1365-2141.2003.04575.x","volume":"122","author":"P Valent","year":"2003","unstructured":"Valent P, Akin C, Sperr WR, Horny HP, Arock M, Lechner K et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003; 122: 695\u2013717.","journal-title":"Br J Haematol"},{"key":"BF1705245_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/(SICI)1096-8652(199801)57:1<24::AID-AJH4>3.0.CO;2-3","volume":"57","author":"D Przepiorka","year":"1998","unstructured":"Przepiorka D, Giralt S, Khouri I, Champlin R, Bueso-Ramos C . Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol 1998; 57: 24\u201328.","journal-title":"Am J Hematol"},{"key":"BF1705245_CR6","first-page":"413","volume":"8","author":"D Ronnov-Jessen","year":"1991","unstructured":"Ronnov-Jessen D, Lovgreen NP, Horn T . Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome. Bone Marrow Transplant 1991; 8: 413\u2013415.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705245_CR7","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1182\/blood.V84.9.2954.2954","volume":"84","author":"M Fodinger","year":"1994","unstructured":"Fodinger M, Fritsch G, Winkler K, Emminger W, Mitterbauer G, Gadner H et al. Origin of human mast cells: development from transplanted hematopoietic stem cells after allogeneic bone marrow transplantation. Blood 1994; 84: 2954\u20132959.","journal-title":"Blood"},{"key":"BF1705245_CR8","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/sj.bmt.1704627","volume":"34","author":"A Spyridonidis","year":"2004","unstructured":"Spyridonidis A, Thomas AK, Bertz H, Zeiser R, Schmitt-Graff A, Lindemann A et al. Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34: 515\u2013519.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705245_CR9","doi-asserted-by":"publisher","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","volume":"92","author":"H Nagata","year":"1995","unstructured":"Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y et al. Identification of a Point Mutation in the Catalytic Domain of the Protooncogene c-kit in Peripheral Blood Mononuclear Cells of Patients who Have Mastocytosis with an Associated Hematologic Disorder. Proc Natl Acad Sci USA 1995; 92: 10560\u201310564.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF1705245_CR10","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/blood.V94.9.3234","volume":"94","author":"R Childs","year":"1999","unstructured":"Childs R, Clave E, Contentin D, Jayasekera D, Hensel N, Leitman S et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor chimerism precedes alloimmune responses. Blood 1999; 94: 3234\u20133241.","journal-title":"Blood"},{"key":"BF1705245_CR11","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/sj.bmt.1704231","volume":"32","author":"E Sloand","year":"2003","unstructured":"Sloand E, Childs RW, Solomon S, Greene A, Young NS, Barrett AJ . The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure hronic myelogenous leukemia. Bone Marrow Transplant 2003; 32: 897\u2013901.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705245_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/sj.bmt.1703648","volume":"30","author":"R Nakamura","year":"2002","unstructured":"Nakamura R, Cortez K, Solomon S, Battiwalla M, Gill VJ, Hensel N et al. High-dose acyclovir and preemptive gancyclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2002; 30: 235\u2013242.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705245_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/sj.bmt.1701043","volume":"21","author":"WY Au","year":"1998","unstructured":"Au WY, Chan AC, Lie AK, Chen FE, Liang R, Kwong YL . Recurrent isolated extramedullary relapses as granulocytic sarcomas following allogeneic bone marrow transplantation for acute myeloid leukemia. Bone Marrow Transplant. 1998; 21: 205\u2013208.","journal-title":"Bone Marrow Transplant."},{"key":"BF1705245_CR14","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/sj.bmt.1702488","volume":"26","author":"KH Lee","year":"2000","unstructured":"Lee KH, Lee JH, Kim S, Lee JS, Kim SH, Kim WK . High frequency of extramedullary relapse of acute leukemia after allogeneic bone marrow transplantation. Bone Marrow Transplant 2000; 26: 147\u2013152.","journal-title":"Bone Marrow Transplant"},{"key":"BF1705245_CR15","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","volume":"102","author":"HC Kluin-Nelemans","year":"2003","unstructured":"Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van\u2019t Wout JW, Verhoef G, Gerritis WB et al. Cladribine therapy for systemic mastocytosis. Blood 2003; 102: 4270\u20134276.","journal-title":"Blood"},{"key":"BF1705245_CR16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJM200101253440415","volume":"344","author":"A Tefferi","year":"2001","unstructured":"Tefferi A, Li CY, Butterfield JH, Hoagland HC . Treatment of systemic mast-cell disease with cladribine. N Engl J Med 2001; 344: 307\u2013309.","journal-title":"N Engl J Med"},{"key":"BF1705245_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0145-2126(03)00185-1","volume":"28","author":"A Pardanani","year":"2004","unstructured":"Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A . Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 2004; 28: 127\u2013131.","journal-title":"Leuk Res"},{"key":"BF1705245_CR18","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","volume":"362","author":"A Pardanani","year":"2003","unstructured":"Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC et al. Imatinib for systemic mast-cell disease. Lancet 2003; 362: 535\u2013536.","journal-title":"Lancet"},{"key":"BF1705245_CR19","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa025217","volume":"348","author":"J Cools","year":"2003","unstructured":"Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201\u20131214.","journal-title":"N Engl J Med"},{"key":"BF1705245_CR20","doi-asserted-by":"publisher","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","volume":"101","author":"AD Klion","year":"2003","unstructured":"Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101: 4660\u20134666.","journal-title":"Blood"},{"key":"BF1705245_CR21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","volume":"103","author":"AD Klion","year":"2004","unstructured":"Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004; 103: 473\u2013478.","journal-title":"Blood"},{"key":"BF1705245_CR22","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","volume":"103","author":"C Akin","year":"2004","unstructured":"Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD . A novel form of systemic mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004; 103: 3222\u20133225.","journal-title":"Blood"},{"key":"BF1705245_CR23","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.1182\/blood-2004-06-2189","volume":"104","author":"AS Corbin","year":"2004","unstructured":"Corbin AS, Griswold IJ, La Rosee P, Yee KW, Heinrich MC, Reimer CL et al. Sensitivity of oncogeneic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood 2004; 104: 3754\u20133757.","journal-title":"Blood"},{"key":"BF1705245_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1182\/blood-2004-12-4771","volume":"106","author":"AS Corbin","year":"2005","unstructured":"Corbin AS, Demehri S, Griswold IJ, Wang Y, Metcalf III CA, Sundaranoorthi R et al. In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood 2005; 106: 227\u2013234.","journal-title":"Blood"},{"key":"BF1705245_CR25","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","volume":"106","author":"JD Growney","year":"2005","unstructured":"Growney JD, Clark JJ, Adelsperger J, Stone R, Fabbro D, Criffin JD et al. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 2005; 106: 721\u2013724.","journal-title":"Blood"},{"key":"BF1705245_CR26","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","volume":"106","author":"J Gotlib","year":"2005","unstructured":"Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005; 106: 2865\u20132870.","journal-title":"Blood"},{"key":"BF1705245_CR27","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1182\/blood-2004-08-3247","volume":"105","author":"A Tanaka","year":"2005","unstructured":"Tanaka A, Konno M, Muto S, Kambe N, Morii E, Nakahata T et al. A novel NF-{kappa}B inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 2005; 105: 2324\u20132331.","journal-title":"Blood"},{"key":"BF1705245_CR28","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1182\/blood-2003-07-2477","volume":"103","author":"G Fumo","year":"2004","unstructured":"Fumo G, Akin C, Metcalfe DD, Neckers L . 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. Blood 2004; 103: 1078\u20131084.","journal-title":"Blood"},{"key":"BF1705245_CR29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/sj.leu.2403686","volume":"19","author":"J Hasford","year":"2005","unstructured":"Hasford J, Pfirrmann M, Hochhaus A . How long will chronic myeloid leukemia patients treated with imatinib mesylate live? Leukemia 2005; 19: 497\u2013499.","journal-title":"Leukemia"},{"key":"BF1705245_CR30","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1634\/theoncologist.9-3-259","volume":"9","author":"RM Stone","year":"2004","unstructured":"Stone RM . Optimizing treatment of chronic myeloid leukemia: a rational approach. Oncologist 2004; 9: 259\u2013270.","journal-title":"Oncologist"},{"key":"BF1705245_CR31","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1056\/NEJMe030009","volume":"348","author":"K Peggs","year":"2003","unstructured":"Peggs K, Mackinnon S . Imatinib mesylate \u2013 the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003; 348: 1048\u20131050.","journal-title":"N Engl J Med"},{"key":"BF1705245_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0065-230X(04)91001-9","volume":"91","author":"BJ Druker","year":"2004","unstructured":"Druker BJ . Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004; 91: 1\u201330.","journal-title":"Adv Cancer Res"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1705245","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1705245.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1705245.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:11:05Z","timestamp":1648080665000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1705245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,9]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,2,1]]}},"alternative-id":["BF1705245"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1705245","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,9]]},"assertion":[{"value":"5 September 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2005","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2005","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2006","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}